Paytm shares are set to remain in focus after the RBI cancelled Paytm Payments Bank’s licence, prompting its closure. The company expects no material impact due to the prior separation. While Bernstein flags concerns over regulatory tone, it retains a positive view, seeing limited business disruption and potential licensing opportunities ahead.
Sun Pharma deal structurally strong, debt the only overhang: Amit Khurana
Market expert Amit Khurana offers insights on key corporate and regulatory developments. Sun Pharma’s acquisition is seen as strategically sound, though debt requires careful management.